# Rifaximin as a Modulator of Microbial Translocation and Immune Activation

> **NCT01466595** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 73 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT01466595
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2018-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466595, "Rifaximin as a Modulator of Microbial Translocation and Immune Activation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01466595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*